OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
1-Year Return
4.17%
This Quarter Return
+15.95%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$41.9M
AUM Growth
-$4.22M
(-9.2%)
Cap. Flow
-$8.75M
Cap. Flow
% of AUM
-20.88%
Top 10 Holdings %
Top 10 Hldgs %
48.42%
Holding
52
New
2
Increased
17
Reduced
26
Closed
5
Top Buys
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$3.23M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$2.04M |
| 3 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$1.14M |
| 4 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$591K |
| 5 |
Fortress Biotech
FBIO
|
$374K |
Top Sells
| 1 |
SPDR S&P Biotech ETF
XBI
|
$5.52M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$5.37M |
| 3 |
iShares Biotechnology ETF
IBB
|
$2.06M |
| 4 |
Biogen
BIIB
|
$884K |
| 5 |
Amgen
AMGN
|
$848K |
Sector Composition
| 1 | Healthcare | 97.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ultragenyx Pharmaceutical
RARE
$3.01B
| $468K | 1.12% |
6,134
-177
| -3% | -$13.5K |
|
27
Bio-Techne
TECH
$8.23B
| $458K | 1.09% |
8,968
+1,340
| +18% | +$68.4K |
|
28
Acadia Pharmaceuticals
ACAD
$4.3B
| $432K | 1.03% |
20,828
+5,500
| +36% | +$114K |
|
29
Neurocrine Biosciences
NBIX
$13.9B
| $417K | 1% |
3,391
+326
| +11% | +$40.1K |
|
30
Axsome Therapeutics
AXSM
$6.21B
| $415K | 0.99% |
120,150
-13,350
| -10% | -$46.1K |
|
31
IQVIA
IQV
$31.3B
| $409K | 0.98% |
3,156
+367
| +13% | +$47.6K |
|
32
Precigen
PGEN
$1.36B
| $409K | 0.98% |
23,780
+6,200
| +35% | +$107K |
|
|
CKPT
33
DELISTED
Checkpoint Therapeutics
CKPT
| $404K | 0.96% |
11,276
| – | – |
|
34
Akebia Therapeutics
AKBA
$801M
| $397K | 0.95% |
45,004
-5,000
| -10% | -$44.1K |
|
|
35
Amgen
AMGN
$151B
| $382K | 0.91% |
1,841
-4,089
| -69% | -$848K |
|
36
Charles River Laboratories
CRL
$7.99B
| $380K | 0.91% |
2,826
+92
| +3% | +$12.4K |
|
|
37
Fortress Biotech
FBIO
$84.5M
| $374K | 0.89% |
+15,602
| New | +$374K |
|
|
38
Biogen
BIIB
$20.5B
| $365K | 0.87% |
1,032
-2,500
| -71% | -$884K |
|
39
United Therapeutics
UTHR
$17.2B
| $359K | 0.86% |
2,805
+145
| +5% | +$18.6K |
|
40
Grifois
GRFS
$6.74B
| $351K | 0.84% |
16,445
+4,003
| +32% | +$85.4K |
|
41
Gilead Sciences
GILD
$140B
| $350K | 0.84% |
4,533
+282
| +7% | +$21.8K |
|
42
Exelixis
EXEL
$10.1B
| $292K | 0.7% |
16,475
+2,920
| +22% | +$51.8K |
|
|
BLUE
43
DELISTED
bluebird bio
BLUE
| $284K | 0.68% |
150
+24
| +19% | +$45.4K |
|
|
PRTK
44
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $175K | 0.42% |
18,000
-2,000
| -10% | -$19.4K |
|
|
CFRX
45
DELISTED
ContraFect Corporation
CFRX
| $140K | 0.33% |
84
-10
| -11% | -$16.7K |
|
|
SCTL
46
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $81K | 0.19% |
12,659
-1,407
| -10% | -$9K |
|
47
SCYNEXIS
SCYX
$36.4M
| $36K | 0.09% |
2,997
-333
| -10% | -$4K |
|
|
48
iShares Biotechnology ETF
IBB
$5.68B
| – | – |
-18,750
| Closed | -$2.06M |
|
|
PGNX
49
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| – | – |
-10,891
| Closed | -$88K |
|
|
MDCO
50
DELISTED
Medicines Co
MDCO
| – | – |
-7,000
| Closed | -$257K |
|